Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Long Term Follow up Dry Eye Disease

In brief

The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).

Key facts

Study ID

NCT03920215

Run by

Oyster Point Pharma, Inc.

People needed

101

Starts

2018-08-15

Expected to finish

2019-09-20

Last updated by the study team

2023-11-01

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have been enrolled in the OPP-002 study
• Have received at least one dose of the study drug/placebo in OPP-002 study
• Completed the OPP-002 study to Visit 5
• Have provided verbal and written informed consent

You may not qualify if…

• Have discontinued prior to Visit 5 in the OPP-002 study.

Where it is running

• Newport Beach — Newport Beach, California, United States
• Indianapolis — Indianapolis, Indiana, United States
• Andover — Andover, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.